Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 5/20 | 0.46 |
| ▸ | GPR183 | P32249 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.45 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23850291 | 0.93 | FAAH (0.52) | FAAHUSP2GPR183CYP3A4CYP2D6 | |
| SCHEMBL23850564 | 0.91 | USP2 (0.53) | FAAHUSP2GPR183CYP3A4CYP2D6 | |
| SCHEMBL23850259 | 0.90 | USP2 (0.49) | FAAHUSP2GPR183CYP3A4CYP2D6 | |
| SCHEMBL25258995 | 0.85 | RORC (0.47) | USP2GPR183CYP3A4CYP2D6TSHR | |
| SCHEMBL23850533 | 0.81 | RORC (0.52) | FAAHUSP2CYP3A4CYP2D6TSHR | |
| SCHEMBL25146284 | 0.81 | ENPP2 (0.42) | FAAHUSP2GPR183CYP3A4CYP2D6 | |
| SCHEMBL30700371 | 0.80 | ENPP2 (0.43) | FAAHGPR183CYP3A4CYP2D6TSHR | |
| SCHEMBL30700172 | 0.80 | ENPP2 (0.43) | FAAHGPR183CYP3A4CYP2D6TSHR | |
| SCHEMBL30409855 | 0.80 | MGLL (0.46) | FAAHGPR183ENPP2ATXN2MGLL | |
| SCHEMBL30700114 | 0.80 | ENPP2 (0.41) | FAAHUSP2GPR183CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | FAAH 2296/4885USP2 3410/4885GPR183 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.